Loading...
OTCM
IPIX
Market cap155kUSD
Jul 08, Last price  
0.00USD
1Q
-62.50%
Jan 2017
-99.97%
IPO
-99.85%
Name

Innovation Pharmaceuticals Inc

Chart & Performance

D1W1MN
OTCM:IPIX chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
28.47%
Rev. gr., 5y
%
Revenues
0k
-100.00%
000000733,4380000000423,000018,0000
Net income
-3m
L-55.01%
-34,122-47,161-510,193-1,485,331-3,433,400-5,938,297-4,894,402-3,224,482-8,247,000-13,145,000-12,852,000-15,536,000-16,362,000-9,071,000-6,648,000-13,872,000-7,041,000-3,168,000
CFO
-2m
L-66.46%
-622-5,911-80,500-211,480-1,109,293-735,703-693,859-1,907,490-7,510,000-13,071,000-9,887,000-11,711,000-13,278,000-6,332,000-4,156,000-9,495,000-6,280,000-2,106,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Innovation Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to the development of small molecule therapies. Its pipeline targets a range of medical areas, including inflammatory diseases, cancer, dermatology, and infectious conditions. The company's lead drug candidate, Brilacidin, is currently in development for treating oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. Furthermore, Innovation Pharmaceuticals is advancing Kevetrin, an anti-cancer compound being investigated for ovarian cancer. The company holds a license agreement with Alfasigma S.p.A. and has a collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. Established in 2005 and headquartered in Wakefield, Massachusetts, the firm operated as Cellceutix Corporation until its name change to Innovation Pharmaceuticals Inc. in June 2017.
URL
http://www.ipharminc.com/
IPO date
Apr 02, 2007
Employees
4
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2023‑062022‑062021‑062020‑062019‑062018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT